26 completed, 16 terminated, 13 withdrawn, 3 unknown. 41 Phase 2, 28 Phase 1, 7 Phase 3, 1 Early Phase 1.
Follow epacadostat: new trials by email Literature Review of epacadostat trials Research Report on epacadostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma retifanlimab, epacadostat, INCAGN02385 - Urothelial Carcinoma | Phase 2 | Terminated | Incyte Corporation | 30 | 2022-01-14 | 2025-10-30 |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. retifanlimab, epacadostat, pemigatinib - Endometrial Cancer | Phase 2 | Completed | Incyte Corporation | 206 | 2021-01-26 | 2026-06-11 |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Durvalumab, Epacadostat - Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma | Phase 2 | Withdrawn | Alain Algazi | 2020-12-01 | 2020-10-26 | |
| Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Epacadostat, Bevacizumab, Radiation therapy - Glioma, Glioblastoma | Phase 2 | Completed | Washington University School of Medicine | 51 | 2020-04-20 | 2025-11-21 |
| Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Epacadostat, Short-course radiation therapy, CAPOX chemotherapy - Rectal Cancer | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 49 | 2020-01-06 | 2026-02-11 |
| Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer Epacadostat, Pembrolizumab - ATM Gene Mutation, Deleterious BRCA1 Gene Mutation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-07-31 | 2019-05-30 | |
| A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies Epacadostat - Solid Tumor | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 | 2019-06-06 | 2021-08-26 |
| Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study Pembrolizumab, Epacadostat - Muscle-invasive Bladder Cancer | Phase 2 | Withdrawn | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-05-22 | 2021-02-26 | |
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat ImmunoPulse, Epacadostat, Pembrolizumab - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Chase Heaton, MD | 14 | 2019-05-02 | 2023-05-09 |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360 - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 | 2019-03-22 | 2020-07-02 |
| Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer Epacadostat, Pembrolizumab - Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2018-12-21 | 2024-07-26 |
| Epacadostat, Cladribine and Cytarabine (ECC) in AML Epacadostat, Cladribine, Cytarabine - AML, Relapse | Phase 1 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2018-12-01 | 2018-09-11 | |
| ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-10-01 | 2026-05-29 | |
| Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA) - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | James J Lee | 2018-09-30 | 2018-08-28 | |
| A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma Epacadostat + pembrolizumab - Recurrent/ Metastatic Endometrial Carcinoma | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2018-09-01 | 2018-10-09 | |
| A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Pembrolizumab, epacadostat - Head and Neck Cancer | Phase 2 | Withdrawn | University of Chicago | 2018-09-01 | 2018-01-04 | |
| Epacadostat, Idarubicin and Cytarabine (EIC) in AML Epacadostat, Idarubicin, Cytarabine - AML | Phase 1 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2018-09-01 | 2018-09-11 | |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Retifanlimab, Epacadostat, INCB050465 - Unresectable or Metastatic Solid Tumors | Phase 1 | Completed | Incyte Corporation | 83 | 2018-08-17 | 2023-02-21 |
| Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab - Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-07-01 | 2022-03-08 | |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) M7824, N-803, MVA-BN-Brachyury - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2018-05-01 | 2025-09-30 |
Showing 20 of 60. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (10) · Parkinson Disease 4, Autosomal Dominant Lewy Body (9) · Head and Neck Neoplasms (8) · Melanoma (8) · Ovarian Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (8) · Lung Neoplasms (6) · Fallopian Tube Neoplasms (5) · Neoplasms (5) · Carcinoma, Transitional Cell (4) · Colorectal Neoplasms (4) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3) · Glioblastoma (3) · Lymphoma (3)
Incyte Corporation (24) · National Cancer Institute (NCI) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University of Chicago (3) · City of Hope Medical Center (2) · Insel Gruppe AG, University Hospital Bern (2) · Roswell Park Cancer Institute (2) · Washington University School of Medicine (2) · Aduro Biotech, Inc. (1) · Alain Algazi (1) · Chao Huang (1) · Chase Heaton, MD (1) · Columbia University (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fox Chase Cancer Center (1)
United States (52) · Canada (10) · Italy (10) · United Kingdom (10) · Australia (8) · Spain (8) · Russia (7) · South Korea (7) · France (6) · Ireland (6) · Japan (6) · Germany (5) · Israel (5) · Taiwan (5) · Turkey (Türkiye) (5)
Mark Jones, MD (6) · Lance Leopold, MD (5) · Kunle Odunsi (2) · Lance Leopold, M.D. (2) · Tanguy Seiwert, MD (2) · Alain P Algazi, MD (1) · Andrea Necchi, MD (1) · Chao Huang, MD (1) · Chase Heaton, MD (1) · Craig Slingluff (1) · Diane Hershock, MD (1) · Dung Le, M.D. (1) · Emese Zsiros, MD (1) · Fred Zheng, MD (1) · George A Fisher, MD (1)
PMID 28698009, PMID 29395863, PMID 30227893, PMID 30894212, PMID 31221619, PMID 32564277, PMID 33602696, PMID 34622229, PMID 35288468, PMID 36156099, PMID 36309837, PMID 38530565, PMID 39054430, PMID 39054462, PMID 39054467, PMID 39054476, PMID 39054485, PMID 39054491, PMID 42498485
2017 (7), 2016 (3), P30CA016056 (2), U01CA154967 (2), 2015 (1), P01CA247886 (1), P30CA015704 (1), P30CA016672 (1), R01CA278197 (1), U10CA180868 (1)